University joins Sanofi Pasteur to develop human vaccines

January 14 / 127

University CFO Allan Tait with Jean-Phillipe Proust, Associate Vice President Vaccines, Asia, Australia and India for Sanofi Pasteur
University CFO Allan Tait with Jean-Phillipe Proust, Associate Vice President Vaccines, Asia, Australia and India for Sanofi Pasteur

The University has signed a Memorandum of Understanding (MOU) with Sanofi Pasteur, the vaccine division of French integrated healthcare leader Sanofi, to work together to develop immune-boosters and vaccines.

The agreement encompasses programs in infectious diseases, microbiology and immunology with a potential to look at other vaccine candidates. 

Joint project teams from the University and Sanofi Pasteur will collaborate on the development and execution of specific research programs.

The global healthcare leader will provide support to University researchers in developing relevant technologies, and will have the right of first refusal to acquire exclusive, worldwide licenses to develop and commercialise the technology.

University of Melbourne Deputy Vice-Chancellor (Research) Professor James McCluskey welcomed the strengthening of the strategic alliance.

“The University is excited to continue the strong alliance with Sanofi Pasteur to work towards developing the next generation of vaccines to protect the population against infectious diseases,” he said.

Sanofi Pasteur has partnered with the University on other projects, including developing an investigative vaccine to treat gingivitis.

 The company produces more than 1 billion doses of vaccines yearly to immunise more than 500 million people in the world. 

The alliance was facilitated by UoM Commercial Limited, the University’s Commercial Engagement Services company. 

 

Editorial Enquiries

Got a story?

Staff are encouraged to submit stories. There are some important steps in preparing a media-ready story.  Email musse-editor@unimelb.edu.au

Share/Save